Regeneron 8-K: Executive Comp/Officer Changes Reported Jan 26

TL;DR

**Regeneron filed an 8-K about executive changes and compensation, but the details aren't public yet.**

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 26, 2024. This filing is categorized under 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'. While the filing indicates a change in executive or director compensation, the specific details of these arrangements or personnel changes are not provided within the accessible text. This matters to investors because changes in executive compensation or leadership can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.

Why It Matters

Changes in executive compensation or officer appointments can reflect strategic shifts or performance incentives, directly influencing investor confidence and the company's future direction.

Risk Assessment

Risk Level: medium — The filing indicates changes in executive compensation or officers, which can be either positive or negative, but the lack of specific details creates uncertainty.

Analyst Insight

A smart investor would monitor Regeneron's subsequent filings or press releases for specific details on the reported executive changes and compensation arrangements, as these could provide clearer insights into the company's strategic direction and financial health.

Key Numbers

• $0.001 — par value per share (the stated par value for Regeneron's Common Stock)
• 000-19034 — Commission File Number (Regeneron's SEC file number)
• 13-3444607 — I.R.S. Employer Identification No. (Regeneron's IRS EIN)

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
• NASDAQ Global Select Market (company) — the exchange where Regeneron's Common Stock is registered
• $0.001 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• Further details regarding the specific compensatory arrangements or officer changes will be disclosed in a subsequent filing or announcement. (REGENERON PHARMACEUTICALS, INC.) — medium confidence, target: 2024-03-31

FAQ

From the Filing

0001104659-24-008807.txt : 20240131 0001104659-24-008807.hdr.sgml : 20240131 20240131161757 ACCESSION NUMBER: 0001104659-24-008807 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240126 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 24583137 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 tm244671d1_8k.htm FORM 8-K false 0000872589 0000872589 2024-01-26 2024-01-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 31, 2024 ( January 26, 2024 )   REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)   New York (State or other jurisdiction of incorporation)   000-19034   13-3444607 (Commission File Number)   (I.R.S. Employer Identification No.)     777 Old Saw Mill River Road , Tarrytown , New York   10591-6707 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 914 ) 847-7000   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On January 26, 2024, based on a previously disclosed Chief Financial Officer succession plan, Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice Presid